Elutia Inc. reported third quarter 2025 net sales of $3.3 million, down from $3.7 million in the same period of 2024. Net sales of SimpliDerm were $2.4 million, compared to $3.1 million in the prior year quarter, while net sales of Cardiovascular products rose to $0.9 million from $0.6 million. Gross margin was 55.8%, up from 48.9%. The company reported a net loss from discontinued operations of $3.5 million, compared to a net loss of $2.1 million in the previous year. Adjusted EBITDA was a loss of $2.7 million, similar to the prior year. As of September 30, 2025, cash balance was $4.7 million. On October 1, 2025, Elutia closed the $88 million sale of its BioEnvelope business to Boston Scientific Corporation, receiving $80.3 million, of which $27.8 million was used to pay off its loan facility and $8 million was placed in escrow. The proceeds will help fund the development of NXT-41x.